News
iStock-894635244

GBT heads to FDA with sickle cell drug voxelotor

Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of sickle cell disease drug voxelotor as part of a filing for accelerated approval.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences